Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer
AbstractIn the past few years, impressing improvements have been made in the treatment of advanced colorectal cancer. Following decades of modest achievements, in which it was just a matter of dose and schedule for 5-FU and leucovorin—the only treatment then available—first, the development of irinotecan and oxaliplatin, and then the use of the two biologicals, bevacizumab and cetuximab, have dramatically improved the life expectancy of our colorectal cancer patients...
- Abstract views: 908
- FULL TEXT: 141
Copyright (c) 2011 Camillo Porta
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.